The mid-stream (MSU) is urine from the bladder, which carries the information clinicians need to accurately identify and diagnose a UTI, or in the case of antenatal patients, make sure all is well.
[More]
Novartis announced today that the US Food and Drug Administration has approved Ilaris (canakinumab) for the treatment of active systemic juvenile idiopathic arthritis in patients aged 2 years and older.
[More]
Giving patients better access to primary health care could save nearly $4 billion a year in unnecessary emergency room visits for a single common complaint - urinary tract infections - according to a study by the Vattikuti Urology Institute at Henry Ford Hospital in Detroit.
[More]
Almirall, S.A. (ALM:MC) and Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline results from AUGMENT/COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA) for the treatment of Chronic Obstructive Pulmonary Disease (COPD), delivered in the Pressair™ inhaler (Genuair® outside the USA).
[More]
Forest Laboratories, Inc. and Almirall, S.A. today announced positive topline results from AUGMENT COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide and formoterol fumarate, delivered in the Pressair (Genuair outside the USA) inhaler.
[More]
Avanir Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate), recommending NUEDEXTA be approved for the treatment of pseudobulbar affect, irrespective of neurologic cause.
[More]
Schizophrenia patients experiencing relapse are 29 times more likely than healthy individuals to have a urinary tract infection, researchers report.
[More]
The U.S. Food and Drug Administration today approved Invokana (canaglifozin) tablets, used with diet and exercise, to improve glycemic control in adults with type 2 diabetes.
[More]
Patients at Michigan hospitals are less likely to experience a urinary tract infection caused by a catheter than at other hospitals in the country, according to a new study by the University of Michigan.
[More]
A new study by British scientists reveals that motile Escherichia coli isolates demonstrated significant activation of NF-κB signaling suggesting that flagellin plays a key role in up-regulating the host innate defences against urinary tract infections (UTIs).
[More]
Antibiotic-resistant Escherichia coli (E. coli) continues to proliferate, driven largely by expansion of a strain of E. coli know as sequence type ST131. A new study points to hospitals and long-term care facilities (LTCF) as settings in which this antibiotic-resistant strain is increasingly found.
[More]
In a new phase III trial mirabegron, a β3-adrenoceptor agonist, given once daily for 12 weeks, reduced the frequency of incontinence episodes and number of daily urinations, and improved urgency and nocturia in adults with overactive bladder compared to those in a placebo group.
[More]
Study results suggest that a “traffic light” system for categorizing the severity of infections in children fails to detect a substantial number of serious bacterial infections, particularly urinary tract infections.
[More]
UCB announced today two new regulatory filings with the US Food and Drug Administration (FDA) and with the European Medicines Agency (EMA) to extend the marketing authorization for Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA) and for adult patients with active axial spondyloarthritis (axSpA).
[More]
Family doctors need to lower their threshold of suspicion for urinary tract infection in children, according to UK research.
[More]
Santarus, Inc. announced today the U.S. commercial launch of UCERIS (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis.
[More]
Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
[More]
There is general agreement among hospital infection preventionists (IPs) with respect to which practices have weak or strong evidence supporting their use to prevent healthcare-associated infection, according to a new study published in the February issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology (APIC).
[More]
Pfizer Inc. said today that the United States District Court for the District of Delaware ruled that Pfizer's patent covering a method for using sirolimus, the active ingredient in RAPAMUNE®, for the inhibition of organ transplant rejection is valid and infringed.
[More]
Western babies are potty trained later these days and need diapers until an average of three years of age. But even infants can be potty trained. A study by researchers at Sahlgrenska Academy, University of Gothenburg, Sweden, followed 47 infants and their mothers in Vietnam - where potty training starts at birth and the need for diapers is usually eliminated by nine months of age.
[More]